These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

993 related items for PubMed ID: 31617496

  • 1. Clinical features and poor prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapid progressive interstitial lung disease.
    Motegi SI, Sekiguchi A, Toki S, Kishi C, Endo Y, Yasuda M, Ikeuchi H, Sakairi T, Hara K, Yamaguchi K, Maeno T, Hiromura K, Ishikawa O.
    Eur J Dermatol; 2019 Oct 01; 29(5):511-517. PubMed ID: 31617496
    [Abstract] [Full Text] [Related]

  • 2. Low positive titer of anti-melanoma differentiation-associated gene 5 antibody is not associated with a poor long-term outcome of interstitial lung disease in patients with dermatomyositis.
    Sakamoto S, Okamoto M, Kaieda S, Fujimoto K, Nagata S, Tominaga M, Nakamura M, Zaizen Y, Nouno T, Koga T, Kawayama T, Kuwana M, Ida H, Hoshino T.
    Respir Investig; 2018 Nov 01; 56(6):464-472. PubMed ID: 30150008
    [Abstract] [Full Text] [Related]

  • 3. Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody-positive Dermatomyositis-associated Interstitial Lung Disease.
    Fujisawa T, Hozumi H, Yasui H, Suzuki Y, Karayama M, Furuhashi K, Enomoto N, Nakamura Y, Inui N, Suda T.
    J Rheumatol; 2019 Aug 01; 46(8):935-942. PubMed ID: 31092718
    [Abstract] [Full Text] [Related]

  • 4. Differential clinical features of patients with clinically amyopathic dermatomyositis who have circulating anti-MDA5 autoantibodies with or without myositis-associated autoantibodies.
    Yamaguchi K, Yamaguchi A, Kashiwagi C, Sawada Y, Taguchi K, Umetsu K, Oshima K, Uchida M, Suzuki M, Kono S, Takemura M, Masubuchi H, Kitahara S, Hara K, Maeno T, Motegi SI, Muro Y, Sakairi T, Hisada T, Kurabayashi M.
    Respir Med; 2018 Jul 01; 140():1-5. PubMed ID: 29957268
    [Abstract] [Full Text] [Related]

  • 5. Prognostic values of anti-Ro52 antibodies in anti-MDA5-positive clinically amyopathic dermatomyositis associated with interstitial lung disease.
    Xu A, Ye Y, Fu Q, Lian X, Chen S, Guo Q, Lu LJ, Dai M, Lv X, Bao C.
    Rheumatology (Oxford); 2021 Jul 01; 60(7):3343-3351. PubMed ID: 33331866
    [Abstract] [Full Text] [Related]

  • 6. Clinical spectrum and therapeutics in Canadian patients with anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis: a case-based review.
    Huang K, Vinik O, Shojania K, Yeung J, Shupak R, Nimmo M, Avina-Zubieta JA.
    Rheumatol Int; 2019 Nov 01; 39(11):1971-1981. PubMed ID: 31375890
    [Abstract] [Full Text] [Related]

  • 7. Clinical Features of Anti-MDA5 Antibody-positive Rapidly Progressive Interstitial Lung Disease without Signs of Dermatomyositis.
    Sakamoto N, Ishimoto H, Nakashima S, Yura H, Miyamura T, Okuno D, Hara A, Kitazaki T, Kakugawa T, Ishimatsu Y, Satoh M, Mukae H.
    Intern Med; 2019 Mar 15; 58(6):837-841. PubMed ID: 30449789
    [Abstract] [Full Text] [Related]

  • 8. Comparison of characteristics and anti-MDA5 antibody distribution and effect between clinically amyopathic dermatomyositis and classic dermatomyositis: a retrospective case-control study.
    Ji Q, Pan W, Zhang D, Hou Y, Wang Z.
    Front Immunol; 2023 Mar 15; 14():1237209. PubMed ID: 38098481
    [Abstract] [Full Text] [Related]

  • 9. Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis.
    Matsushita T, Mizumaki K, Kano M, Yagi N, Tennichi M, Takeuchi A, Okamoto Y, Hamaguchi Y, Murakami A, Hasegawa M, Kuwana M, Fujimoto M, Takehara K.
    Br J Dermatol; 2017 Feb 15; 176(2):395-402. PubMed ID: 27452897
    [Abstract] [Full Text] [Related]

  • 10. Association of Serum Soluble CD163 with Polymyositis and Dermatomyositis, Especially in Anti-MDA5 Antibody-positive Cases.
    Kawasumi H, Katsumata Y, Nishino A, Hirahara S, Kawaguchi Y, Kuwana M, Yamanaka H.
    J Rheumatol; 2018 Jul 15; 45(7):947-955. PubMed ID: 29657141
    [Abstract] [Full Text] [Related]

  • 11. Rapidly progressive interstitial lung disease due to anti-MDA5 antibodies without skin involvement: a case report and literature review.
    González-Moreno J, Raya-Cruz M, Losada-Lopez I, Cacheda AP, Oliver C, Colom B.
    Rheumatol Int; 2018 Jul 15; 38(7):1293-1296. PubMed ID: 29417209
    [Abstract] [Full Text] [Related]

  • 12. Successful treatment of plasma exchange for rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis: A case report.
    Endo Y, Koga T, Suzuki T, Hara K, Ishida M, Fujita Y, Tsuji S, Takatani A, Shimizu T, Sumiyoshi R, Igawa T, Umeda M, Fukui S, Nishino A, Kawashiri SY, Iwamoto N, Ichinose K, Tamai M, Nakamura H, Origuchi T, Kuwana M, Kawakami A.
    Medicine (Baltimore); 2018 Apr 15; 97(15):e0436. PubMed ID: 29642214
    [Abstract] [Full Text] [Related]

  • 13. Predictive factors of rapidly progressive-interstitial lung disease in patients with clinically amyopathic dermatomyositis.
    Xu Y, Yang CS, Li YJ, Liu XD, Wang JN, Zhao Q, Xiao WG, Yang PT.
    Clin Rheumatol; 2016 Jan 15; 35(1):113-6. PubMed ID: 26660480
    [Abstract] [Full Text] [Related]

  • 14. [Three cases report of juvenile dermatomyositis with positive anti-melanoma differentiation associated gene 5 (MDA5) antibody and severe interstitial lung disease and literature review].
    Hou J, Zhou ZX, Li JG, Xu YJ, Ding YC.
    Zhonghua Er Ke Za Zhi; 2019 Dec 02; 57(12):928-933. PubMed ID: 31795559
    [Abstract] [Full Text] [Related]

  • 15. Early initiation of plasma exchange therapy for a patient with anti-MDA5 autoantibody-positive dermatomyositis developing rapidly progressive interstitial lung disease.
    Sasaki N, Ishii A, Kurabayashi T, Sugiyama M, Izumi Y, Nakagome Y, Hirano K, Sasaki S, Kondo Y, Nogi S, Nishikawa A, Hosono Y, Yamada C, Sato S.
    Mod Rheumatol Case Rep; 2021 Jan 02; 5(1):87-94. PubMed ID: 33048020
    [Abstract] [Full Text] [Related]

  • 16. Serum cytokine profiles of patients with interstitial lung disease associated with anti-CADM-140/MDA5 antibody positive amyopathic dermatomyositis.
    Takada T, Aoki A, Asakawa K, Sakagami T, Moriyama H, Narita I, Sato S.
    Respir Med; 2015 Sep 02; 109(9):1174-80. PubMed ID: 26187000
    [Abstract] [Full Text] [Related]

  • 17. Different Multivariable Risk Factors for Rapid Progressive Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis and Anti-Synthetase Syndrome.
    Zuo Y, Ye L, Chen F, Shen Y, Lu X, Wang G, Shu X.
    Front Immunol; 2022 Sep 02; 13():845988. PubMed ID: 35320936
    [Abstract] [Full Text] [Related]

  • 18. Successful classification of macrophage-mannose receptor CD206 in severity of anti-MDA5 antibody positive dermatomyositis associated ILD.
    Horiike Y, Suzuki Y, Fujisawa T, Yasui H, Karayama M, Hozumi H, Furuhashi K, Enomoto N, Nakamura Y, Inui N, Ogawa N, Suda T.
    Rheumatology (Oxford); 2019 Dec 01; 58(12):2143-2152. PubMed ID: 31143953
    [Abstract] [Full Text] [Related]

  • 19. Predictors of Poor Outcome of Anti-MDA5-Associated Rapidly Progressive Interstitial Lung Disease in a Chinese Cohort with Dermatomyositis.
    Li Y, Li Y, Wu J, Miao M, Gao X, Cai W, Shao M, Zhang X, Xu Y, Cong L, He J, Sun X.
    J Immunol Res; 2020 Dec 01; 2020():2024869. PubMed ID: 33299896
    [Abstract] [Full Text] [Related]

  • 20. Anti-MDA5 Antibody-positive Clinically Amyopathic Dermatomyositis with Rapidly Progressing Interstitial Lung Disease Successfully Treated by Initiation of Combined Immunosuppressive Therapy Plus Plasma Exchange and Subsequently Switching Tacrolimus to Tofacitinib.
    Yamazoe M, Takeda K, Nagano Y, Nagano K, Kato K, Inoue T, Horiuchi K, Kamada K.
    Intern Med; 2024 Sep 15; 63(18):2571-2578. PubMed ID: 38346740
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 50.